|Bid||0.8350 x 3000|
|Ask||0.8900 x 3000|
|Day's Range||0.8200 - 0.8845|
|52 Week Range||0.7600 - 1.7800|
|Beta (3Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.76|
Interpace Diagnostics Group Inc is engaged in developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for diagnosis and management. Interpace Diagnostics Group Inc had annual average EBITDA growth of 6.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with IDXG.
Business Progress and Recent Accomplishments Highlighted and Discussed Further on Conference Call PARSIPPANY, NJ, March 19, 2019 -- Interpace Diagnostics Group, Inc..
If you want to know who really controls Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), then you'll have to look at the makeup of its share registry. Institutions often own shares inRead More...
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”) announced today that the Pittsburgh Business Times has designated Interpace Diagnostics as its 2018 Top Life Sciences Company award winner. The Pittsburgh location serves as the Company’s largest laboratory and provides a wide variety of services including cytology, molecular testing, and pathology. All four of Interpace’s DNA-based testing products along with their clinical testing are performed at the Pittsburgh lab.
Interpace to Host Fourth Quarter and Full Year 2018 Results Conference Call/Webcast PARSIPPANY, NJ, Feb. 28, 2019 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG).
Interpace Diagnostics Group, Inc. (IDXG) announced today that BMJ Open Gastroenterology, an on-line, peer-reviewed, open access gastroenterology journal dedicated to publishing high-quality medical research from all disciplines and therapeutic areas of gastroenterology, has provided the first independent evidence that BarreGEN®, the Company’s lead pipeline product, performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to the visible appearance of advanced histology. This is the first publication resulting from work related to the Company’s ongoing Clinical Experience Program (CEP) under which several sites across the country are using BarreGEN to provide input on its clinical utility in a real-world setting.
Interpace Diagnostics Group (IDXG) today announced the Company will attend the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will host one-on-one meetings through the BIO CEO & Investor Conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green or Wiktoria O’Hare at Edison Advisors.
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) today announced the closing of its previously announced underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per share. Interpace has also granted the underwriter a 30-day option to purchase up to an additional 1,400,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Interpace intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures, and acquisition of new technologies and businesses.
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per share, less underwriting discounts and commissions. Interpace also granted the underwriter a 30-day option to purchase up to an additional 1,400,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Interpace expects to receive aggregate gross proceeds of approximately $7 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) announced today that it intends to offer and sell shares of its common stock in a registered underwritten public offering. In addition, Interpace also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock equal to 15% of the shares to be sold in the offering to cover over-allotments, if any. Interpace intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures, and acquisition of new technologies and businesses.
Interpace Diagnostics Group (IDXG) today announced that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Tuesday, January 29th at 1:30 pm Eastern Standard Time in Studio 1. A high-definition, video webcast of the presentation will be available the following day on the Company's website (www.interpacediagnostics.com), and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on the new investor portal created by Noble called Channelchek: www.channelchek.com. The webcast will be archived on the company's website, the NobleCon website and on Channelchek.com for 90 days following the event.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has finalized the validation of its third specimen type for its molecular thyroid tests ThyGeNEX™ and ThyraMIR®. Interpace has expanded its services again to now also process specimens prepared in formalin fixed, paraffin-embedded (FFPE) samples. The Company initiated a partnering arrangement with the Dianon Systems Inc. division of LabCorp (LH) and certain regional labs to provide customers with a one-stop service for molecular testing for their indeterminate thyroid nodules.
In 2016 Jack Stover was appointed CEO of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will Read More...
Interpace Diagnostics Group (IDXG) has entered in to an Agreement with the University of Maryland Medical System (UMMS), which will provide physicians access to ThyGeNEXT™, ThyraMIR®, and PancraGEN® across the entire UMMS network. Physicians can utilize ThyGeNEXT™ and ThyraMIR® to assess indeterminate thyroid nodules and PancraGEN® for indeterminate pancreatic cysts and solid lesions. The UMMS network is a university-based regional health care system focused on serving the health care needs of the State of Maryland.
Interpace Diagnostics Group, Inc. (IDXG) announced today that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized Interpace Diagnostics as a top bioinformatics solutions company. This year CIO Applications ranked Interpace as a Top 10 Company for providing bioinformatics solutions through the Company’s extensive database of molecular testing results. In 2017, Interpace was recognized as a Top 20 Bioinformatics Solutions Provider.
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Interpace Diagnostics Group Inc (NASDAQ:IDXG), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is Read More...
Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,, Nov. 13, 2018 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial.
Interpace Diagnostics Group, Inc. (IDXG) announced today that the Company has been invited to participate at the 9th Annual Craig-Hallum Alpha Select Conference to be held on November 15, 2018 at the Sheraton New York Times Square Hotel. Companies, such as Interpace, have been individually selected by the Craig-Hallum research team based on several factors including above average growth prospects, attractive business models, competitive advantage, unappreciated value and strong management teams. The Alpha Select List companies will be presented to top institutional investors and analysts from across the country.
Interpace Diagnostics Group, Inc. (IDXG) announced today that the Blue Cross Blue Shield (“BCBS”) Federal Employee Health Benefit Program (“FEHBP”) has extended coverage of ThyGeNEXT™ and ThyraMIR® to its 5.3 million covered lives including federal employees, retirees and their families. The FEHBP relies on consumer choices among competing private plans to determine costs, premiums, benefits, and service and currently has a 66% federal employee and retiree plan participation rate. The rule-in characteristic utilizes next generation sequencing of the patient’s DNA and RNA along with rule-out capabilities of micro-RNA providing physicians with clinically actionable test results. Based on current performance, over 90% of the Company’s ThyGeNEXT™ cases are reflexed to ThyraMIR® for additional assessment.